Search
Search Results
##search.searchResults.foundPlural##
-
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3930PDF: 1491HTML: 9187Untitled: 277Untitled: 183Untitled: 168Untitled: 164Untitled: 180Untitled: 338 -
DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
277648PDF: 1789HTML: 3862 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1652PDF: 1173HTML: 200 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3309PDF: 1465HTML: 3998 -
THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association
1051PDF: 1044HTML: 95 -
TYROSINE KINASE INHIBITORS AND INTERFERON
2847PDF: 1436HTML: 3045Cover Letter: 207 -
CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE ELDERLY
2872PDF: 1098HTML: 3029 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2212PDF: 1042HTML: 1981Characteristic of study group: 196 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1301PDF: 1195HTML: 446 -
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection CML and COVID-19
3255PDF: 1529HTML: 420 -
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
4052PDF: 1923HTML: 5225Table 1: 190 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
1020PDF: 1194Suppl. Files: 146HTML: 68 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1620PDF: 1092HTML: 116 -
Interstitial pneumonia triggered by H1N1 influenza A virus as the initial presentation of chronic myeloid leukemia
867PDF: 473HTML: 124Suppl. Files: 312 -
Is laboratory monitoring useful in DOACs management?
833PDF: 799HTML: 107 -
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: NON-RANDOMIZED STUDY WITH A MAXIMUM FOLLOW-UP OF MORE THAN 22 YEARS
1539PDF: 904HTML: 1952Figure: 169Tables: 185ALL revision 1: 190response to reviewer: 180 -
Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia
2913PDF: 687HTML: 1933figure 1: 168figure 2: 176 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
2850PDF: 1227HTML: 2698Figure 1: 171 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
4735PDF: 2826HTML: 2278 -
PEDIATRIC MASTOCYTOSIS: AN UPDATE Chldren' Mastocytosis
1823HTML: 1442PDF: 1078 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3544PDF: 1633HTML: 2674 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1519PDF: 941HTML: 222 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9042PDF: 6052HTML: 87949Fig.1b: 183Fig.1c: 188Fig.2a: 176Fig.2b: 175Fig.4: 188Fig.2c: 183Fig.3: 181Tab.1: 225Tab.2: 206Tab.3: 188Tab.4: 220Fig1a: 181 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1236PDF: 982HTML: 209 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2075PDF: 1517HTML: 283 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
935PDF: 511HTML: 192 -
A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA
3230PDF: 1330HTML: 4129
1 - 47 of 47 items







